Actively Recruiting

Age: 18Years +
All Genders
ID05131100

Korean Post-marketing Surveillance for Somavert

Led by Pfizer · Updated on 2025-07-04

100

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to observe the safety and effectiveness of Somavert in people with acromegaly during routine medical care in Korea. It is an observational study conducted as part of regulatory requirements by the Ministry of Food and Drug Safety (MFDS) to monitor the drug after it has been marketed. Pfizer sponsors this study to gather real-world data on Somavert use. Participants in this study receive Somavert as they would in normal medical practice without any additional treatments or interventions from the study. The study follows patients from the start of treatment through about 52 weeks, tracking usage as it naturally occurs in healthcare settings. During the study, researchers will monitor participants for any adverse events from the beginning until 28 days after the last Somavert dose. They will also assess clinical improvement over approximately 52 weeks. The study involves routine medical assessments and data collection during regular visits, with no extra procedures required. Participants will be followed throughout this period to understand how Somavert performs in real-world use.

CONDITIONS

Brief Title

Korean Regulatory Post Marketing Surveillance for Somavert

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • All patients prescribed Somavert according to local label and investigator's judgement
  • Patients treated under routine medical practice settings in Korea
  • Patients aged 18 years or older
  • Patients with acromegaly
Not Eligible

You will not qualify if you...

  • Patients who have contraindications for Somavert

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to approximately 52 weeks

Participants who undergo routine care with Somavert are observed for safety and clinical improvement.

Visits as per routine medical practice

Trial Site Locations

Total: 1 location

1

Pfizer

Seoul, South Korea, 01037

Actively Recruiting

Loading map...

Research Team

P

Pfizer CT.gov Call Center

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here